Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)

SIMPLE SUMMARY: We reported that palbociclib plus exemestane with ovarian function suppression (with leuprolide) led to significantly longer median progression-free survival compared with capecitabine in premenopausal metastatic breast cancer patients. We also evaluated differences of patient report...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Soohyeon, Im, Seock-Ah, Kim, Gun Min, Jung, Kyung Hae, Kang, Seok Yun, Park, In Hae, Kim, Jee Hyun, Lee, Kyoung Eun, Ahn, Hee Kyung, Lee, Moon Hee, Kim, Hee-Jun, Kim, Han Jo, Lee, Jong In, Koh, Su-Jin, Park, Yeon Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694364/
https://www.ncbi.nlm.nih.gov/pubmed/33167305
http://dx.doi.org/10.3390/cancers12113265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694364/
https://www.ncbi.nlm.nih.gov/pubmed/33167305
http://dx.doi.org/10.3390/cancers12113265

Ejemplares similares